Antimicrobial peptides and viral fusion peptides : How different they are?

Protein and Peptide Letters

Volumn 16, Issue 7, 2009, Pages 743-750

  Joanne, P ^a   Nicolas, P ^a   El Amri, C ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Antimicrobial peptides; GXXXG motif; Hydrophobicity; Membrane disruptive properties; Structural plasticity; Viral fusion peptides

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; PEPTIDE; VIRUS FUSION PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CELL MEMBRANE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; METABOLISM; MOLECULAR GENETICS; PHYSICAL CHEMISTRY; VIRUS ENTRY;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL MEMBRANE; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PHYSICOCHEMICAL PROCESSES; VIRAL FUSION PROTEINS; VIRUS INTERNALIZATION;

EID: 67849131062     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986609788681814     Document Type: Article

References (82)

1. Yeaman, M.R.; Yount, N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev., 2003, 55(1), 27-55.
2. Epand, R.F.; Epand, R.M.; Monaco, V.; Stoia, S.; Formaggio, F.; Crisma, M.; Toniolo, C. The antimicrobial peptide trichogin and its interaction with phospholipid membranes. Eur. J. Biochem., 1999, 266(3), 1021-1028.
3. Papo, N.; Shai, Y. Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes? Peptides, 2003, 24(11), 1693-1703.
4. Shai, Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta, 1999, 1462(1-2), 55-70.
5. Huang, H.W. Molecular mechanism of antimicrobial peptides: the origin of cooperativity. Biochim. Biophys. Acta, 2006, 1758(9), 1292-1302.
6. Bechinger, B.; Lohner, K. Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim. Biophys. Acta, 2006, 1758(9), 1529-1539.
7. Otvos, L., Jr. Antibacterial peptides and proteins with multiple cellular targets. J. Pept. Sci., 2005, 11(11), 697-706.
8. Eckert, D.M.; Kim, P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem., 2001, 70, 777-810.
9. Durell, S.R.; Martin, I.; Ruysschaert, J.M.; Shai, Y.; Blumenthal, R. What studies of fusion peptides tell us about viral envelope glycoprotein-mediated membrane fusion (review). Mol. Membr. Biol., 1997, 14(3), 97-112.
10. Del Angel, V.D.; Dupuis, F.; Mornon, J.P.; Callebaut, I. Viral fusion peptides and identification of membrane-interacting segments. Biochem. Biophys. Res. Commun., 2002, 293(4), 1153-1160.
11. Shai, Y. Functional domains within fusion proteins: prospectives for development of peptide inhibitors of viral cell fusion. Biosci. Rep., 2000, 20(6), 535-555.
12. Lorin, A.; Charloteaux, B.; Fridmann-Sirkis, Y.; Thomas, A.; Shai, Y.; Brasseur, R. Mode of membrane interaction and fusogenic properties of a de novo transmembrane model peptide depend on the length of the hydrophobic core. J. Biol. Chem., 2007, 282(25), 18388-18396.
13. Nieva, J.L.; Agirre, A. Are fusion peptides a good model to study viral cell fusion? Biochim. Biophys. Acta, 2003, 1614(1), 104-115.
14. Aranda, F.J.; Teruel, J.A.; Ortiz, A. Interaction of a synthetic peptide corresponding to the N-terminus of canine distemper virus fusion protein with phospholipid vesicles: a biophysical study. Biochim. Biophys. Acta, 2003, 1618(1), 51-58.
15. Epand, R.M. Fusion peptides and the mechanism of viral fusion. Biochim. Biophys. Acta, 2003, 1614(1), 116-121.
16. Mangoni, M.L.; Grovale, N.; Giorgi, A.; Mignogna, G.; Simmaco, M.; Barra, D. Structure-function relationships in bombinins H, antimicrobial peptides from Bombina skin secretions. Peptides, 2000, 21(11), 1673-1679. (Pubitemid 30945691)
17. Chan, D.I.; Prenner, E.J.; Vogel, H.J. Tryptophan-and argininerich antimicrobial peptides: structures and mechanisms of action. Biochim. Biophys. Acta, 2006, 1758(9), 1184-1202.
18. Hofmann, M.W.; Weise, K.; Ollesch, J.; Agrawal, P.; Stalz, H.; Stelzer, W.; Hulsbergen, F.; de Groot, H.; Gerwert, K.; Reed, J.; Langosch, D. De novo design of conformationally flexible transmembrane peptides driving membrane fusion. Proc. Natl. Acad. Sci. USA, 2004, 101(41), 14776-14781.
19. Nicolas, P.; Mor, A. Peptides as weapons against microorganisms in the chemical defense system of vertebrates. Annu. Rev. Microbiol., 1995, 49, 277-304.
20. Nicolas, P.; El Amri, C. The dermaseptin superfamily: a genebased combinatorial library of antimicrobial peptides. Biochim. Biophys. Acta, 2008, in press.
21. Haque, M.E.; Koppaka, V.; Axelsen, P.H.; Lentz, B.R. Properties and structures of the influenza and HIV fusion peptides on lipid membranes: implications for a role in fusion. Biophys. J., 2005, 89(5), 3183-3194.
22. Vaccaro, L.; Cross, K.J.; Kleinjung, J.; Straus, S.K.; Thomas, D.J.; Wharton, S.A.; Skehel, J.J.; Fraternali, F. Plasticity of influenza haemagglutinin fusion peptides and their interaction with lipid bilayers. Biophys. J., 2005, 88(1), 25-36.
23. Nagpal, S.; Kaur, K.J.; Jain, D.; Salunke, D.M. Plasticity in structure and interactions is critical for the action of indolicidin, an antibacterial peptide of innate immune origin. Protein Sci., 2002, 11(9), 2158-2167.
24. Lorin, A.; Thomas, A.; Stroobant, V.; Brasseur, R.; Lins, L. Lipiddestabilising properties of a peptide with structural plasticity. Chem. Phys. Lipids, 2006, 141(1-2), 185-196.
25. Li, Y.; Tamm, L.K. Structure and plasticity of the human immunodeficiency virus gp41 fusion domain in lipid micelles and bilayers. Biophys. J., 2007, 93(3), 876-885.
26. Deshayes, S.; Decaffmeyer, M.; Brasseur, R.; Thomas, A. Structural polymorphism of two CPP: an important parameter of activity. Biochim. Biophys. Acta, 2008, 1778(5), 1197-1205.
27. El Amri, C.; Nicolas, P. Plasticins: membrane-damaging peptides with,chameleon-like' properties. Cell. Mol. Life Sci., 2008, 65(6), 895-909.
28. Wimmer, R.; Andersen, K.K.; Vad, B.; Davidsen, M.; Molgaard, S.; Nesgaard, L.W.; Kristensen, H.H.; Otzen, D.E. Versatile interactions of the antimicrobial peptide novispirin with detergents and lipids. Biochemistry, 2006, 45(2), 481-497.
29. El Kirat, K.; Dufrene, Y.F.; Lins, L.; Brasseur, R. The SIV tilted peptide induces cylindrical reverse micelles in supported lipid bilayers. Biochemistry, 2006, 45(30), 9336-9341.
30. Lins, L.; Brasseur, R. Tilted peptides: a structural motif involved in protein membrane insertion? J. Pept. Sci., 2008, 14(4), 416-422.
31. Harris, F.; Wallace, J.; Phoenix, D.A. Use of hydrophobic moment plot methodology to aid the identification of oblique orientated alpha-helices. Mol. Membr. Biol., 2000, 17(4), 201-207.
32. Dennison, S.R.; Harris, F.; Phoenix, D.A. Are oblique orientated alpha-helices used by antimicrobial peptides for membrane invasion? Protein Pept. Lett., 2005, 12(1), 27-29.
33. Weise, K.; Reed, J. Fusion peptides and transmembrane domains of fusion proteins are characterized by different but specific structural properties. Chembiochem, 2008, 9(6), 934-943.
34. Buzon, V.; Padros, E.; Cladera, J. Interaction of fusion peptides from HIV gp41 with membranes: a time-resolved membrane binding, lipid mixing, and structural study. Biochemistry, 2005, 44(40), 13354-13364.
35. Castano, S.; Desbat, B. Structure and orientation study of fusion peptide FP23 of gp41 from HIV-1 alone or inserted into various lipid membrane models (mono-, bi-and multibi-layers) by FT-IR spectroscopies and Brewster angle microscopy. Biochim. Biophys. Acta, 2005, 1715(2), 81-95.
36. Reichert, J.; Grasnick, D.; Afonin, S.; Buerck, J.; Wadhwani, P.; Ulrich, A.S. A critical evaluation of the conformational requirements of fusogenic peptides in membranes. Eur. Biophys. J., 2007, 36(4-5), 405-413.
37. Bruston, F.; Lacombe, C.; Zimmermann, K.; Piesse, C.; Nicolas, P.; El Amri, C. Structural malleability of plasticins: preorganized conformations in solution and relevance for antimicrobial activity. Biopolymers, 2007, 86(1), 42-56.
38. El Amri, C.; Bruston, F.; Joanne, P.; Lacombe, C.; Nicolas, P. Intrinsic flexibility and structural adaptability of Plasticins membrane-damaging peptides as a strategy for functional versatility. Eur. Biophys. J., 2007, 36(8), 901-909.
39. Cole, A.M.; Liao, H.I.; Ganz, T.; Yang, O.O. Antibacterial activity of peptides derived from envelope glycoproteins of HIV-1. FEBS Lett., 2003, 535(1-3), 195-199.
40. Mancheno, J.M.; Onaderra, M.; Martinez del Pozo, A.; Diaz-Achirica, P.; Andreu, D.; Rivas, L.; Gavilanes, J.G. Release of lipid vesicle contents by an antibacterial cecropin A-melittin hybrid peptide. Biochemistry, 1996, 35(30), 9892-9899.
41. Cummings, J.E.; Vanderlick, T.K. Aggregation and hemi-fusion of anionic vesicles induced by the antimicrobial peptide cryptdin-4. Biochim. Biophys. Acta, 2007, 1768(7), 1796-1804.
42. Yount, N.Y.; Yeaman, M.R. Immunocontinuum: perspectives in antimicrobial peptide mechanisms of action and resistance. Protein Pept. Lett., 2005, 12(1), 49-67.
43. Oren, Z.; Lerman, J.C.; Gudmundsson, G.H.; Agerberth, B.; Shai, Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem. J., 1999, 341(Pt. 3), 501-513.
44. Lau, W.L.; Ege, D.S.; Lear, J.D.; Hammer, D.A.; DeGrado, W.F. Oligomerization of fusogenic peptides promotes membrane fusion by enhancing membrane destabilization. Biophys. J., 2004, 86(1Pt 1), 272-284.
45. Sammalkorpi, M.; Lazaridis, T. Configuration of influenza hemagglutinin fusion peptide monomers and oligomers in membranes. Biochim. Biophys. Acta, 2007, 1768(1), 30-38.
46. Zhou, F.X.; Merianos, H.J.; Brunger, A.T.; Engelman, D.M. Polar residues drive association of polyleucine transmembrane helices. Proc. Natl. Acad. Sci. USA, 2001, 98(5), 2250-2255.
47. Lemmon, M.A.; Flanagan, J.M.; Hunt, J.F.; Adair, B.D.; Bormann, B.J.; Dempsey, C.E.; Engelman, D.M. Glycophorin A dimerization is driven by specific interactions between transmembrane alphahelices. J. Biol. Chem., 1992, 267(11), 7683-7689.
48. Glukhov, E.; Stark, M.; Burrows, L.L.; Deber, C.M. Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J. Biol. Chem., 2005, 280(40), 33960-33967.
49. Glaser, R.W.; Sachse, C.; Durr, U.H.; Wadhwani, P.; Afonin, S.; Strandberg, E.; Ulrich, A.S. Concentration-dependent realignment of the antimicrobial peptide PGLa in lipid membranes observed by solid-state 19F-NMR. Biophys. J., 2005, 88(5), 3392-3397.
50. Rogne, P.; Fimland, G.; Nissen-Meyer, J.; Kristiansen, P.E. Threedimensional structure of the two peptides that constitute the twopeptide bacteriocin lactococcin G. Biochim. Biophys. Acta, 2008, 1784(3), 543-554.
51. Miyauchi, K.; Curran, R.; Matthews, E.; Komano, J.; Hoshino, T.; Engelman, D.M.; Matsuda, Z. Mutations of conserved glycine residues within the membrane-spanning domain of human immunodeficiency virus type 1 gp41 can inhibit membrane fusion and incorporation of Env onto virions. Jpn. J. Infect. Dis., 2006, 59(2), 77-84.
52. Arbely, E.; Granot, Z.; Kass, I.; Orly, J.; Arkin, I.T. A trimerizing GxxxG motif is uniquely inserted in the severe acute respiratory syndrome (SARS) coronavirus spike protein transmembrane domain. Biochemistry, 2006, 45(38), 11349-11356.
53. Cleverley, D.Z.; Lenard, J. The transmembrane domain in viral fusion: essential role for a conserved glycine residue in vesicular stomatitis virus G protein. Proc. Natl. Acad. Sci. USA, 1998, 95(7), 3425-3430.
54. Lewis, R.N.; McElhaney, R.N. Fourier transform infrared spectroscopy in the study of lipid phase transitions in model and biological membranes: practical considerations. Methods Mol. Biol., 2007, 400, 207-226.
55. El Amri, C.; Lacombe, C.; Zimmerman, K.; Ladram, A.; Amiche, M.; Nicolas, P.; Bruston, F. The plasticins: membrane adsorption, lipid disorders, and biological activity. Biochemistry, 2006, 45(48), 14285-14297.
56. Lewis, R.N.; Mannock, D.A.; McElhaney, R.N. Differential scanning calorimetry in the study of lipid phase transitions in model and biological membranes: practical considerations. Methods Mol. Biol., 2007, 400, 171-195.
57. Klappe, K.; Wilschut, J.; Nir, S.; Hoekstra, D. Parameters affecting fusion between Sendai virus and liposomes. Role of viral proteins, liposome composition, and pH. Biochemistry, 1986, 25(25), 8252-8260.
58. Haywood, A.M.; Boyer, B.P. Effect of lipid composition upon fusion of liposomes with Sendai virus membranes. Biochemistry, 1984, 23(18), 4161-4166.
59. Fonteijn, T.A.; Engberts, J.B.; Nir, S.; Hoekstra, D. Asymmetric fusion between synthetic di-n-dodecylphosphate vesicles and virus membranes. Biochim. Biophys. Acta, 1992, 1110(2), 185-192.
60. Teissier, E.; Pecheur, E.I. Lipids as modulators of membrane fusion mediated by viral fusion proteins. Eur. Biophys. J., 2007, 36(8), 887-899.
61. Freitas, M.S.; Gaspar, L.P.; Lorenzoni, M.; Almeida, F.C.; Tinoco, L.W.; Almeida, M.S.; Maia, L.F.; Degreve, L.; Valente, A.P.; Silva, J.L. Structure of the Ebola fusion peptide in a membranemimetic environment and the interaction with lipid rafts. J. Biol. Chem., 2007, 282(37), 27306-27314.
62. Buzon, V.; Cladera, J. Effect of cholesterol on the interaction of the HIV GP41 fusion peptide with model membranes. importance of the membrane dipole potential. Biochemistry, 2006, 45(51), 15768-15775.
63. Veiga, A.S.; Santos, N.C.; Loura, L.M.; Fedorov, A.; Castanho, M.A. HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers: putative correlation with improved efficiency. J. Am. Chem. Soc., 2004, 126(45), 14758-14763.
64. Epand, R.M.; Epand, R.F. Modulation of membrane curvature by peptides. Biopolymers., 2000, 55(5), 358-363.
65. Siegel, D.P.; Epand, R.M. Effect of influenza hemagglutinin fusion peptide on lamellar/inverted phase transitions in dipalmitoleoylphosphatidylethanolamine: implications for membrane fusion mechanisms. Biochim. Biophys. Acta, 2000, 1468(1-2), 87-98.
66. Epand, R.F.; Zhang, Y.L.; Mirzabekov, T.; Kagan, B.; Silberstein, A.; Hubbell, W.L.; Epand, R.M.; Chakraborti, S.; Dimitrov, D.S.; Anderson, W.F.; Rozenberg-Adler, Y. Membrane activity of an amphiphilic alpha-helical membrane-proximal cytoplasmic domain of the MoMuLV envelope glycoprotein. Exp. Mol. Pathol., 2008, 84(1), 9-17.
67. Cross, K.J.; Wharton, S.A.; Skehel, J.J.; Wiley, D.C.; Steinhauer, D.A. Studies on influenza haemagglutinin fusion peptide mutants generated by reverse genetics. EMBO J., 2001, 20(16), 4432-4442.
68. Epand, R.M.; Epand, R.F. Relationship between the infectivity of influenza virus and the ability of its fusion peptide to perturb bilayers. Biochem. Biophys. Res. Commun., 1994, 202(3), 1420-1425.
69. Henzler Wildman, K.A.; Lee, D.K.; Ramamoorthy, A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry, 2003, 42(21), 6545-6558.
70. Hallock, K.J.; Lee, D.K.; Ramamoorthy, A. MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain. Biophys. J., 2003, 84(5), 3052-3060.
71. Galdiero, S.; Falanga, A.; Vitiello, M.; D'Isanto, M.; Cantisani, M.; Kampanaraki, A.; Benedetti, E.; Browne, H.; Galdiero, M. Peptides containing membrane-interacting motifs inhibit herpes simplex virus type 1 infectivity. Peptides, 2008, 29(9), 1461-1471.
72. Jiang, S.; Zhao, Q.; Debnath, A.K. Peptide and non-peptide HIV fusion inhibitors. Curr. Pharm. Des., 2002, 8(8), 563-580.
73. He, Y.; Cheng, J.; Li, J.; Qi, Z.; Lu, H.; Dong, M.; Jiang, S.; Dai, Q. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J. Virol., 2008, 82(13), 6349-6358.
74. Pritsker, M.; Jones, P.; Blumenthal, R.; Shai, Y. A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion. Proc. Natl. Acad. Sci. USA, 1998, 95(13), 7287-7292.
75. Munch, J.; Standker, L.; Adermann, K.; Schulz, A.; Schindler, M.; Chinnadurai, R.; Pohlmann, S.; Chaipan, C.; Biet, T.; Peters, T.; Meyer, B.; Wilhelm, D.; Lu, H.; Jing, W.; Jiang, S.; Forssmann, W.G.; Kirchhoff, F. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell, 2007, 129(2), 263-275.
76. Este, J.A.; Telenti, A. HIV entry inhibitors. Lancet, 2007, 370(9581), 81-88.
77. Lorin, C.; Saidi, H.; Belaid, A.; Zairi, A.; Baleux, F.; Hocini, H.; Belec, L.; Hani, K.; Tangy, F. The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. Virology, 2005, 334(2), 264-275.
78. Thomas, C. Frog skin yields antiviral peptides. Nat. Med., 2005, 11(10), 1046.
79. Belaid, A.; Aouni, M.; Khelifa, R.; Trabelsi, A.; Jemmali, M.; Hani, K. In. vitro antiviral activity of dermaseptins against herpes simplex virus type 1. J. Med. Virol., 2002, 66(2), 229-234.
80. VanCompernolle, S.E.; Taylor, R.J.; Oswald-Richter, K.; Jiang, J.; Youree, B.E.; Bowie, J.H.; Tyler, M.J.; Conlon, J.M.; Wade, D.; Aiken, C.; Dermody, T.S.; KewalRamani, V.N.; Rollins-Smith, L.A.; Unutmaz, D. Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells. J. Virol., 2005, 79(18), 11598-11606
81. Kelly, B.A.; Neil, S.J.; McKnight, A.; Santos, J.M.; Sinnis, P.; Jack, E.R.; Middleton, D.A.; Dobson, C.B. Apolipoprotein Ederived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity. FEBS J., 2007, 274(17), 4511-4525.
82. Abrunhosa, F.; Faria, S.; Gomes, P.; Tomaz, I.; Pessoa, J.C.; Andreu, D.; Bastos, M. Interaction and lipid-induced conformation of two cecropin-melittin hybrid peptides depend on peptide and membrane composition. J. Phys. Chem. B, 2005, 109(36), 17311-17319.